Broad-based execution drives further sales and earnings growth
Total Q3 2023 sales +10% and +16% ex COVID
Vaccines sales +33%, +34% ex COVID. Shingrix £0.8 billion +15%, Arexvy sales £0.7 billion
Specialty Medicines sales -1%, +17% ex COVID with HIV +15%
General Medicines sales -2% with impact of generic competition to older products, in part offset by Trelegy +23%
Total operating profit and Total continuing EPS reflects strong growth in the quarter and year to date with lower charges for contingent consideration liabilities remeasurement
Adjusted operating profit +15% and Adjusted EPS +17% reflects strong execution, resilient growth and higher royalty income in part offset by increased investment in R&D, new product launches and a seven percentage point operating profit reduction from lower COVID-19 solutions sales
Q3 2023 Year to Date
£m % AER % CER £m % AER % CER
Turnover 8,147 4 10 22,276 1 2
Turnover ex COVID 8,146 10 16 22,102 12 13
Total operating profit 1,949 64 83 6,172 35 39
Total continuing EPS 36.1p 92 >100 113.0p 54 59
Adjusted operating profit 2,772 6 15 7,034 7 10
Adjusted operating margin % 34.0% 0.8ppts 1.7ppts 31.6% 1.7ppts 2.2ppts
Adjusted EPS 50.4p 7 17 126.2p 11 14
Cash generated from operations 2,508 32 4,415 (24)
R&D delivery underpins longer-term growth outlook
Arexvy approved in Japan as country’s first RSV vaccine for older adults; positive preliminary phase III data in adults aged 50-59 presented at ACIP and support regulatory filings
New Shingrix data demonstrates 100% efficacy in preventing shingles in adults aged 50+ in China; copromotion partnership in China with Zhifei announced, set to begin in 2024
Apretude long-acting treatment approved for HIV prevention in EU; clinical development plans advancing for innovative long-acting treatment and prevention regimens with data anticipated in 2024
Ojjaara approved by US FDA as first and only line agnostic treatment for myelofibrosis patients with anaemia
Jemperli plus chemotherapy approved in US as new frontline treatment for endometrial cancer
Agreement to acquire worldwide rights to Janssen’s JNJ-3989, which may have potential to further increase functional cure rates of bepirovirsen in chronic hepatitis B treatment
2023 guidance upgrade, Q3 2023 dividend of 14p declared, 56.5p expected for full year
Turnover to increase 12 to 13% (from 8 to 10%)
Adjusted operating profit growth 13 to 15% (from 11 to 13%)
Adjusted EPS growth 17 to 20% (from 14 to 17%)

see & read more on
https://www.gsk.com/en-gb/media/press-releases/strong-year-to-date-and-q3-performance-drives-upgrade-to-full-year-guidance/